Encompass Health Corporation (EHC) Company Overview

What does Encompass Health do?

Encompass Health Corporation is a New York Stock Exchange-listed provider focused on inpatient rehabilitation hospitals, or IRFs. Patients typically arrive after a stroke, brain injury, spinal cord injury, hip fracture, major surgery, or another serious condition requiring intensive therapy before returning home. Its care model combines physician supervision, 24-hour nursing, multidisciplinary therapy, and hospital-level support. The corporate overview reports 176 hospitals and a growth strategy centered on adding capacity in underserved markets.

What care is delivered inside an inpatient rehabilitation hospital?

The company’s patient proposition is more intensive than a skilled nursing setting: its care model generally includes three hours of therapy a day, five days a week, frequent physician visits, and continuous nursing. The objective is not simply to stabilize a patient; it is to improve functional independence and discharge the patient safely to the community. That makes clinical outcomes, length of stay, transfer rates, and referral relationships central business metrics.

Why does scale matter in a fragmented market?

Encompass Health describes itself as the largest U.S. owner and operator of IRFs by patients treated, revenue, and hospital count in its 2025 Form 10-K. Scale supports standardized clinical protocols, centralized data, purchasing, recruiting, payor contracting, and development expertise. Yet rehabilitation remains locally competitive: referrals come from physicians and acute-care hospitals, labor markets differ by city, and certificate-of-need rules can limit or delay entry. Encompass Health therefore combines national systems with hospital-level execution.

How does Encompass Health make money?

Encompass Health earns substantially all revenue by treating patients in IRFs. Revenue reflects contracted or regulated reimbursement, not stated gross charges. The economic chain is to obtain referrals, admit eligible patients, provide an intensive rehabilitation stay, collect from government or commercial payors, and manage labor and facility costs tightly enough to produce a margin.

Which revenue stream matters most?

Because Encompass Health now reports one operating segment, investors should not look for a software-like mix shift between divisions. The more useful decomposition is volume, reimbursement per discharge, payor mix, occupancy, and labor intensity. In FY2025, discharges rose 6.0% to 263,299, same-store discharges rose 3.4%, and net patient revenue per discharge increased 3.9% to $21,862.

How do payors determine pricing?

Medicare and Medicare Advantage represented about 82% of FY2025 revenue. Traditional Medicare pays under the IRF prospective payment system, while Medicare Advantage and managed-care rates are negotiated. That creates a strategic tension: Encompass Health has limited ability to pass wage inflation directly through to government payors, but its scale, outcomes data, and cost-effective care can improve its negotiating position with managed-care plans.

What does Encompass Health’s latest quarter show?

The most recent reported financial period is the quarter ended March 31, 2026. Encompass Health’s Q1 2026 earnings release showed growth, while the related Form 10-Q linked the revenue increase primarily to higher volume and favorable pricing.

What changed in Q1 2026?

Why did earnings grow faster than revenue?

Adjusted EBITDA expanded 11.2%, faster than the 9.0% revenue increase, implying modest operating leverage. Salaries and benefits were $818.1 million in Q1 2026, equal to about 51.6% of revenue, compared with 52.4% in Q1 2025. Total operating expenses were $1.285 billion, or approximately 81.0% of revenue, down from roughly 81.7% a year earlier. New hospitals still require ramp-up spending, so the margin improvement is notable given ongoing capacity expansion.

Management raised full-year 2026 guidance after Q1: net operating revenue to $6.375-$6.470 billion, adjusted EBITDA to $1.350-$1.380 billion, and adjusted EPS from continuing operations to $5.89-$6.11. Those ranges frame expectations, but the next reported quarter remains important because Encompass Health scheduled its Q2 2026 results for August 5, 2026.

How did strategic turning points create today’s focused IRF platform?

Encompass Health’s current simplicity is the result of several strategic changes. The company began as HealthSouth, expanded into home health and hospice, unified the businesses under the Encompass Health brand, and later separated the home-based business. The result is a company that can direct capital, management attention, and investor analysis toward inpatient rehabilitation.

Which decisions still matter today?

1. 1984
   Founded as HealthSouth. The original rehabilitation focus created the clinical and hospital-development base that remains central today.
2. 2015
   Acquired Encompass Home Health and Hospice. The transaction broadened the post-acute continuum and later supplied the Encompass brand.
3. 2018
   Changed the corporate name and ticker. The official name change to Encompass Health and ticker EHC reflected an integrated post-acute strategy.
4. 2019
   Completed national rebranding. One identity supported referral recognition and enterprise-wide operating practices.
5. 2022
   Spun off Enhabit Home Health & Hospice. The separation rationale emphasized sharper strategy, capital structures, and management focus for each business.
6. 2025
   Accelerated bed growth. Seven new hospitals added 340 beds, while expansions added another 177 beds, including a 50-bed remote hospital.
7. 2026
   Continued de novo expansion. Q1 added a 49-bed hospital and 44 expansion beds; the current overview now lists 176 hospitals.

Why are bed growth, occupancy, and labor productivity central to returns?

IRFs carry meaningful fixed costs before the next patient arrives. Returns therefore depend on filling licensed beds while maintaining outcomes and controlling staffing. Encompass Health plans six to ten de novo hospitals and 80 to 120 added beds at existing hospitals annually through 2027, increasing long-term capacity but creating near-term construction and ramp-up costs.

Which operating KPIs reveal utilization and productivity?

How did the annual economics improve?

FY2025 revenue increased 10.5%, adjusted EBITDA increased 14.9% to $1.268 billion, and net income attributable to Encompass Health rose 24.2% to $566.2 million. Salaries and benefits declined from 54.0% to 52.5% of revenue, while total operating expenses fell from 83.9% to 82.3%. These changes show why occupancy and labor efficiency matter: small percentage improvements on a nearly $6 billion revenue base can materially change earnings.

What gives Encompass Health a competitive advantage?

Encompass Health competes in a fragmented market against local and national IRF operators, rehabilitation units inside acute-care systems, and alternative post-acute settings such as skilled nursing facilities. Its filing does not define a named peer as the universal competitor because competition is market specific. The company instead argues that clinical outcomes, cost effectiveness, financial strength, and technology differentiate its hospitals.

Which resources are difficult to replicate?

The strongest moat is a bundle rather than one patent or brand: referral relationships, licensed facilities, clinical talent, Joint Commission specialty accreditations, proprietary operating data, and the ability to finance de novo hospitals. As of March 31, 2026, 149 hospitals held at least one disease-specific certification and 148 had stroke rehabilitation accreditation. Joint ventures add another barrier by aligning Encompass Health with acute-care partners in local markets.

Where can the advantage weaken?

How strong are cash flow, liquidity, and capital allocation?

Encompass Health generated $1.176 billion of operating cash flow from continuing operations in FY2025, up from $1.003 billion in FY2024. Capital purchases were $736.4 million, leaving a simple operating-cash-flow-minus-capex figure of about $439.2 million. That is not the company’s adjusted free cash flow definition, but it illustrates the core capital-allocation tension: EHC produces cash and then reinvests a large portion into hospitals, beds, technology, and maintenance.

Can the balance sheet support the development plan?

Liquidity is adequate but not cash-rich in isolation; the model relies on recurring operating cash flow and borrowing capacity. Debt is largely fixed-rate senior notes with major maturities in 2028, 2030, and 2031. That maturity ladder gives management time, but higher development spending can raise revolver usage before new hospitals mature.

How does management divide cash among growth and shareholders?

Who owns EHC stock, and how is it governed?

Encompass Health has dispersed institutional ownership rather than founder control or a dual-class voting structure. The company’s 2026 proxy statement reported 99.4 million shares outstanding for ownership-percentage calculations as of February 12, 2026. Three institutions were listed above the 5% threshold, while directors and executive officers as a group held 1.8%.

What do ownership and board structure signal?

Chief Executive Officer Mark Tarr has led EHC since December 2016 through the rebrand, Enhabit separation, and current development cycle. Most named executives’ 2025 annual incentives assigned 70% weight to adjusted EBITDA and 30% to quality and strategic objectives. Researchers should still test whether growth capital earns adequate returns.

What opportunities and risks could change the outlook?

The opportunity is structural demand from an aging population and an underserved rehabilitation market. New hospitals and bed additions can convert that demand into volume. The principal risks are Medicare concentration, labor availability, regulatory scrutiny, construction execution, and preserving clinical outcomes while scaling.

Which items deserve active monitoring?

The key asymmetry is reimbursement versus labor. EHC cannot directly pass cost increases to Medicare and Medicaid because rates are regulated. If wages rise faster than reimbursement, margins can contract despite healthy demand; stable labor and higher occupancy create the opposite effect.

What is the key takeaway for valuation and monitoring?

A valuation of Encompass Health should begin with hospital economics. Core DCF drivers are mature-hospital discharges, reimbursement per discharge, occupancy, labor cost, de novo opening costs, maintenance versus growth capex, cash conversion, and returns on new beds. Adjusted EBITDA tracks operations and debt capacity, but free cash flow must reflect the capital required to sustain and expand the network.

Which variables should a DCF model emphasize?